CalbaTech Seeks Majority Stake in Qicc
By HospiMedica staff writers
Posted on 18 Jul 2003
New terms that include an option for the future acquisition of majority ownership in Qicc, Ltd. (Ayr, Scotland) have been negotiated by CalbaTech, Inc. (Irvine, CA, USA), which has been taking steps to begin to market Qicc's slide-based diagnostic products in North America.Posted on 18 Jul 2003
CalbaTech's exclusive license with Qicc covers all of the company's manual products in North America as well as the development and distribution of an automated product in both North America and Japan. CalbaTech has recently begun its search for a strategic partner in Japan. The QiccStain immunohisochemistry reagents and kits of Qicc were recently cleared by the US Food and Drug Administration (FDA) under an exemption as a Class I device.
"We believe that current Qicc products will bring near term revenue and support Qicce's projected future products,” said James DeOlden, CEO of CalbaTech. "The potential of an acquisition was a key component in our agreement and it continues to enforce our belief in CalbaTech as a life sciences growth company.”
CalbaTech is focused on acquiring, incubating, and developing early-stage, life science based companies that are developing next-generation products and technologies, both in the United States and the United Kingdom.
Related Links:
Qicc
CalbaTech
New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
New
Automatic Hematology Analyzer
LABAS F9000
New
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
